In a phase 2 study, Ojemda (tovorafenib) led to responses in 43% of adults with melanoma or other solid tumors that carried rare RAF gene changes. Ojemda (tovorafenib) shrank tumors in 10 of 23 adults ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

A three-drug combination helped treatment-resistant melanoma respond again to immune-based therapy in mouse experiments. The ...

Iowa’s cancer incidence has diverged from national declines, prompting a state-funded, two-year investigation into patterns ...

‘What is it all for if it is not to make others aware?’ ...

Lutz Menzel, PhD, formerly of the Department of Radiation Oncology within the Mass General Brigham Cancer Institute, and Tim Padera, PhD, currently of the Mass General Brigham Cancer Institute, are ...

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the developer of cancer immunotherapies, is pressing ahead with plans ...

The INMC analysis links pathological response after neoadjuvant immunotherapy with long-term outcomes in melanoma and ...

Of course, that’s the natural reaction to seeing these super close-up photos of skin lesions, but taking a good look may just ...

Counties with greater proportions of non-Hispanic White residents had lower medical debt prevalence. Medical debt and cancer incidence were generally higher in the South and Southwest and lower in the ...

Publication of the peer-reviewed papers comes as iOnctura awaits readouts from its two fully-enrolled, randomized Phase II ...

Some of the latest research frontiers are investigating the idea of “cancer vaccines” and other so-called targeted treatments ...